Navigation Links
Researchers Identify Targeted Therapy That Can Help Children With Deadly Nerve Cancer
Date:10/17/2019

Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options, according to a study published in October in Cancer Cell.

Neuroblastoma is one of the most common and aggressive pediatric nervous system tumors and generally has a poor prognosis, particularly when it advances in older children. Treatment success for the disease varies, but is exponentially less in adolescent patients, particularly because the disease lacks effective targeted therapies.

The Mount Sinai researchers found that neuroblastoma in older children and adolescents harboring deletions within a gene called ATRX may be responsive to a targeted therapy called tazemetostat. Tazemetostat disables an enzyme called EZH2 that inhibits genes that promote normal neuron development, in turn killing neuroblastoma cells. Neuroblastoma arises in immature nerve cells of the adrenal glands and portions of the spine during the development of the sympathetic nervous system, which controls the body’s “flight or fight” response to stress. EZH2 inhibitors are already being tested in phase I and phase II clinical trials for other cancers, including lymphomas, sarcomas, and other solid tumors, with some favorable results.

“We hypothesized that mutant ATRX proteins contribute to aggressive neuroblastoma,” said Emily Bernstein, PhD, Professor of Oncological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and senior corresponding author. “In this study, we aimed to decipher the underlying biology of these altered proteins in neuroblastoma, a tumor for which effective therapeutic strategies remain obscure, and to exploit identified dependencies.”

Mount Sinai scientists continue to expand this research into the role of the mutant ATRX protein in the laboratory and hope to eventually open a clinical trial with collaborating institutions. Based on this research, they believe that EZH2 inhibitors could also be effective in other ATRX mutant cancers, such as pediatric glioblastoma multiforme and osteosarcoma.

This work was funded by grants from the National Cancer Institute, the U.S. Department of Defense, the National Institutes of Health, and St. Baldrick’s Foundation.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Read the full story at https://www.prweb.com/releases/researchers_identify_targeted_therapy_that_can_help_children_with_deadly_nerve_cancer/prweb16653061.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
2. University Researchers Use Biozoom Scanner To Investigate Relationship Between Stress And Work
3. BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
4. Tisch MS Researchers Announce Breakthrough in Disease Monitoring
5. Northwestern Medicine Researchers Investigate New Stent Technology to Treat Coronary Artery Disease
6. Pharmaceutical Giants Back Researchers in Unique US Competition
7. Kaiser Permanente Researchers Honored for Drug Therapy Study
8. Transparency Life Sciences Partners With Oncology Researchers At Icahn School Of Medicine At Mount Sinai To Assess Metformin In Prostate Cancer
9. Nova Southeastern University Researchers Receive $4.1 Million Grant from Department of Defense to Investigate Gulf War Illness
10. Researchers Use CT and 3-D Printers to Recreate Dinosaur Fossils
11. ideaPoint, Inc. Announces Launch of Multi-Sponsor Portal Providing Researchers Opportunity to Request Access to Clinical Data from Five Global Study Sponsors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2020)... , ... August 26, 2020 , ... As the U.S. ... the daily routine for preventing the Coronavirus. Wear a mask, keep your distance, wash ... advocate Dr. Denis Burkitt said it best in 1977, “How much better it is ...
(Date:8/26/2020)... ... 26, 2020 , ... Hero Life Sciences announced today that it ... ply surgical disposable face masks and N95 respirators in its manufacturing plant located in ... that most Americans are facing in trying to find quality disposable face masks during ...
(Date:8/26/2020)... ... August 26, 2020 , ... NucleusHealth, LLC, ... E. Hooton as President and Chief Executive Officer effective immediately. Dr. Vishal Verma, ... company’s Board of Managers. , Mr. Hooton, a seasoned business executive, joined ...
Breaking Medicine Technology:
(Date:8/28/2020)... JACKSONVILLE, Fla. (PRWEB) , ... August 28, 2020 ... ... that Forcura’s Founder & CEO Craig Mandeville was named an Entrepreneur Of The ... The Year program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... subscription to a customized Lighthouse Health & Wellness mobile app and web-portal. NCPCV ... project. Motorola Solutions Foundation awards grants each year to organizations, such as Destination ...
(Date:8/28/2020)... , ... August 28, 2020 , ... Integrated Viral ... is the first Florida school to deploy its breakthrough Mobile Biodefense Indoor Air Protection ... COVID-19. True North Classical Academy plans to fully reopen equipped with the filtration system ...
(Date:8/28/2020)... ... August 28, 2020 , ... A July 27 ... obese individuals are at an increased risk of developing severe COVID-19 symptoms. The ... COVID-19; however, because the same organ systems that the coronavirus attacks are already ...
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... ... doors! Sikara Medspa is a leading aesthetic and wellness retreat. The practice is ... and surrounding areas of Las Vegas. , Designed to be a sanctuary ...
Breaking Medicine News(10 mins):